Zepbound KwikPen: Doses, Needles, Storage, Cost and Medicare (2026)

Quick answer

As of September 2026, the Zepbound KwikPen is a disposable, single-patient-use prefilled pen that holds 4 fixed weekly doses of tirzepatide, so one pen covers one month of once-weekly treatment; the medicine is tirzepatide, as in the single-dose pen and vial, and what differs is the device, the preservatives in the solution and the storage clock. In practice: attach a new KwikPen-compatible pen needle and prime before every weekly injection, discard the pen 30 days after first use or after the fourth dose even if liquid remains, and never share it. LillyDirect's announcement page, as captured May 4, 2026, lists the KwikPen starting at $299 per month for eligible self-pay patients, and as of September 2026 Medicare's GLP-1 Bridge covers the KwikPen, and no other Zepbound presentation, for $50 per month.

For a current presentation-by-presentation price breakdown, see the Zepbound cost guide.

What is a KwikPen, and what is the Zepbound KwikPen?

KwikPen is a registered trademark of Eli Lilly and Company; the Zepbound label footer says so. The Zepbound KwikPen Instructions for Use describe this one in two sentences: "ZEPBOUND KwikPen is a disposable multi-dose single-patient-use prefilled pen. The Pen contains 4 fixed doses, one dose taken weekly." Nothing is drawn up, measured or refilled, and the pen belongs to one person. Searches also say Zepbound quick pen, kwik pen, multi-dose pen or new pen; all mean this device.

Zepbound itself is tirzepatide, a once-weekly injectable medicine. Where the label says to inject it and why to rotate the site is covered in Zepbound injection sites. Its FDA-approved label indicates it, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. Eli Lilly announced on February 23, 2026 that the FDA had approved a label expansion to include the four-dose KwikPen, which in the company's words "delivers a full month of treatment in one device." New to this class of medicine? Start with what a GLP-1 medication is.

Zepbound KwikPen vs Zepbound pen vs vial: the differences in one table

The active ingredient is the same in all four presentations. What differs is how many doses one container holds, how the dose gets into you, which preservatives are in the solution, and how long the container may stay out of the refrigerator. Every cell comes from the prescribing information and Instructions for Use on DailyMed.

Section 2.4 adds: "If the prescribed ZEPBOUND presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation." A switch between presentations is a retraining event, not a like-for-like swap.

How many doses does a Zepbound KwikPen hold, and can you take a half dose?

Four. Section 3 of the label states that "the multi-dose vials and single-patient-use KwikPen each contain 4 doses." How long does a Zepbound KwikPen last? One month of weekly injections, or 30 days from first use, whichever comes first.

The doses are fixed. There is no half dose: for your weekly dose "you need to turn the dose knob all the way until it stops AND the icon is in dose window," and "Do not count clicks as you select the dose." The pen is not refillable: "After 4 doses, throw away (discard) the Pen, including the unused medicine." Leftover liquid is not a spare dose: section 11 notes that each KwikPen "contains additional volume to allow for device priming," and the Instructions for Use state that "The Pen will prevent you from dialing a full dose after you have given yourself 4 weekly doses. Do not inject the leftover medicine." Also: "Do not transfer ZEPBOUND from your Pen into a syringe." The KwikPen comes in several strengths, one per pen, so a dose change is a prescriber decision and a different pen; how to read a prescription label shows where the strength is printed.

What is in the box, and which pen needles does the KwikPen use?

One KwikPen and no needles. The Instructions for Use list the supplies: the KwikPen, a "KwikPen-compatible Pen Needle (not included)", an alcohol swab, gauze or a cotton ball, and an "FDA-cleared sharps disposal container or household container." Pen needles are a separate purchase; the label names no brand, gauge or length, so that choice belongs to your pharmacist or prescriber.

How to use the Zepbound KwikPen, step by step

Your pharmacist or prescriber should walk you through the device before your first dose, and the manufacturer publishes an official KwikPen overview video with a full transcript on its how-to-use page. The label's 17 steps come to this:

• Wash your hands, pull the cap straight off, and inspect the pen: not expired, not damaged, label matching your prescription, and the medicine not frozen, cloudy, discolored or holding particles.
• Wipe the red inner seal with an alcohol swab and twist on a new capped pen needle: "Always use a new pen needle for each injection to help prevent infections and blocked needles."
• Prime before every weekly injection; priming "removes air from the cartridge and makes sure that your Pen is working correctly." Turn the knob to the prime position, hold the needle up, push the knob in until it stops and hold it while counting slowly; a drop of medicine should appear at the needle tip. If none appears, the label allows a limited number of repeats and one needle change, then "contact Lilly at 1-800-LillyRx (1-800-545-5979)."
• Choose a site (thigh, abdomen away from the belly button, or the back of the upper arm if someone else injects) and rotate weekly.
• Turn the dose knob all the way until it stops and the icon shows in the dose window, insert the needle, push the knob in until it stops, and hold while counting slowly. "A drop of medicine on the needle tip is normal." If the icon is not in the window afterward, reinsert and finish without redialing.
• Unscrew the needle into a sharps container and recap the pen: "Do not store the Pen with the needle attached."

Section 2.4 says the KwikPen "is not recommended for self-administration by those who are visually impaired," and the Instructions for Use say people who are blind or have vision problems should not use the pen without help from a person trained to use it.

Troubleshooting the Zepbound KwikPen

The cap will not come off. "Gently twist the Pen cap back and forth, and then pull the Pen cap straight off."

The dose knob is hard to push. Pushing more slowly "will make it easier to inject"; the needle may be blocked, so "put on a new pen needle and prime the Pen"; or "you may have dust, food, or liquid inside the Pen. Throw the Pen away and get a new Pen."

The pen will not turn to the dose icon. That is the pen doing its job after the fourth dose: "Throw away (discard) the Pen, including the unused medicine. There may not be enough medicine left in the pen to give a full dose."

If you are unsure you received a full dose, do not start over or repeat the injection; call your healthcare provider or 1-800-LillyRx. The same manufacturer page offers a "Check the authenticity of your medicine" tool.

Storage and expiration date: unopened, after first use, at room temperature

What is the expiration date on a Zepbound KwikPen? It is the EXP printed on the pen and carton, and it applies to one situation only: an unopened pen kept in the refrigerator. The single-dose pen and vial have their own storage sentences, quoted in does Zepbound need to be refrigerated. Section 16.2 states that the unopened KwikPen "can be used until the expiration date on the label if kept in the refrigerator." Two 30-day rules override that date once the pen leaves the refrigerator or is used.

Unopened, at room temperature: "throw away unopened multi-dose vial or single-patient-use KwikPen after 30 days."

After first use: keep the pen in its carton, refrigerated at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) or at room temperature up to 86 degrees Fahrenheit (30 degrees Celsius), and then: "Throw away opened multi-dose vial or single-patient-use KwikPen after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it."

People switching presentations get caught out here: the single-dose pen and vial may be kept unrefrigerated "for up to a total of 21 days." For every presentation: never freeze Zepbound, protect it from heat and light, and keep it out of the reach of children.

How to dispose of the KwikPen and pen needles

The label splits disposal into two rules. Pen needles are sharps: "Put your used pen needles in an FDA-cleared sharps disposal container right away after use. Do not throw away (discard) loose pen needles in your household trash." The pen body is not: "Discard the used Pen in your household trash or FDA-cleared sharps disposal container after you have removed the needle."

Without an FDA-cleared container, the FDA's sharps page says that "a heavy-duty plastic household container, such as a laundry detergent container can be used as an alternative," with a tight-fitting, puncture-resistant lid. Community rules govern how a full container is discarded; the label directs state-specific questions to the FDA's safe sharps disposal page.

Can two people share one Zepbound KwikPen?

No, and a fresh needle does not change the answer. The prescribing information carries a numbered warning, section 5.10, written for this device: "Never share ZEPBOUND KwikPen between patients, even if the pen needle is changed. Sharing poses a risk for transmission of blood-borne pathogens." The Medication Guide repeats it in plain language: "You may give other people a serious infection, or get a serious infection from them."

Where to get the Zepbound KwikPen: pharmacies and channels the manufacturer lists

Zepbound is a prescription medicine. Lilly's February 23, 2026 release said that "at this time, Zepbound KwikPen is only available through LillyDirect Pharmacy for new or existing self-pay patients." By May 2026, the LillyDirect announcement page said to "ask your doctor to send your KwikPen prescription to LillyDirect Pharmacy or a local pharmacy of your choice," with "self pay and insurance paths" available, and contrasted the vial, which "is available exclusively through LillyDirect self pay."

The pharmacy service providers LillyDirect names on that page are Prescryptive, Amazon Pharmacy, Fuze Health, Gifthealth and Walmart Pharmacy. TrumpRx.gov, the federal direct-purchase site, routes Zepbound Vial orders "through LillyDirect"; as of September 22, 2026, it lists the vial only, not the KwikPen.

How much does the Zepbound KwikPen cost, and is it the same price as the vial?

Manufacturer figures only, each with its date. As of September 2026, the LillyDirect page captured May 4, 2026 states that the KwikPen is "available in multiple doses, starting at $299 per month for eligible patients. Terms and conditions apply." As of September 2026, Lilly's February 2026 release answers the same-price question directly: "The price of Zepbound is the same for both KwikPen and single-dose vials with Zepbound Self Pay Journey Program. Terms apply. Taxes and fees may apply."

Three cautions. The starting price is for the starting dose, which the LillyDirect page notes is "not approved as a maintenance dose." Lilly's pricing page warns that "the prices patients pay at the pharmacy may be different." And as of September 2026, that page's commercial-insurance line, "as low as $25 for a one- or three-month supply Zepbound single-dose pens," is written for single-dose pens and does not mention the KwikPen. On why no lower-priced approved alternative exists yet, see is there a generic Zepbound.

Does Medicare cover the Zepbound KwikPen?

Yes, under one specific program, and the presentation is the whole point. CMS's Medicare GLP-1 Bridge gives eligible Medicare Part D beneficiaries "access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027," and "will operate outside of the Medicare Part D benefit's coverage and payment flow," so the Part D deductible does not apply. As of September 2026, the Medicare.gov fact sheet lists "Zepbound (KwikPen only)" among covered drugs, states that "the single-dose Zepbound pen and Zepbound vials are NOT covered," and sets the cost at "$50 per month, no matter your income level."

Eligibility has four conditions on the fact sheet: Part D drug coverage, not being eligible for a GLP-1 drug through your Medicare drug plan, none of the listed conditions Part D may already cover, and age plus body mass index criteria. The CMS prior authorization form likewise names "Zepbound (Kwikpen)", and the fact sheet adds: "To get a refill, you don't need a new approval from Medicare as long as you stay on the same drug, even if your dose changes." The fuller walk-through is at Medicare coverage of GLP-1 medicines.

Where the KwikPen fits next to compounded tirzepatide

For someone using compounded tirzepatide from a vial and syringe, what the branded device changes first is regulatory status. The KwikPen is an FDA-approved product with an FDA-approved label; compounded medications are not FDA-approved as final products. The FDA's own page states: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed," and its GLP-1 statement adds that "compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug." The label's limitation of use, that coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended, makes moving between products a prescriber conversation, not a swap. See is compounded tirzepatide safe and 503A vs 503B pharmacies.

Key warnings on the Zepbound label

The label carries a boxed warning about the risk of thyroid C-cell tumors and contraindicates Zepbound in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in anyone with a known serious hypersensitivity to tirzepatide or its excipients. Other warnings cover severe gastrointestinal reactions, kidney injury from dehydration, gallbladder disease, pancreatitis, hypersensitivity, hypoglycemia, diabetic retinopathy complications, and pulmonary aspiration under anesthesia; see Zepbound side effects. Questions about the device go to your healthcare provider or Lilly at 1-800-LillyRx (1-800-545-5979); general questions about telehealth prescribing are answered in the help center.

The bottom line

Four fixed weekly doses of tirzepatide in one disposable, single-patient-use device, and that design explains every rule here: needles not included, prime before each injection, no half doses and no syringes, discard 30 days after first use or after the fourth dose, never shared. As of September 2026, it is the only Zepbound presentation Medicare's GLP-1 Bridge covers. A change of presentation is a new device: ask to be shown how to use it.

This article is for informational purposes only and does not constitute medical advice. Zepbound is a prescription medicine; storage, availability, pricing and coverage details change, so verify them against the current label and the manufacturer's and Medicare's own pages. Medication is prescribed only if a licensed physician determines it is appropriate.

Telehealth prescribing rules differ by state. Read the state-by-state guide.